Study: NCT06709495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Myeloid growth factor administered per institutional standards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Myeloid growth factor administered per institutional standards.